2010
DOI: 10.1056/nejmoa1003466
|View full text |Cite|
|
Sign up to set email alerts
|

Abstract: BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response — administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS A total of 676 HLA-A⋆0201–positive patients with unresectable stage III or IV melanoma, whose di… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

161
9,766
22
223

Year Published

2011
2011
2018
2018

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 12,828 publications
(10,172 citation statements)
references
References 35 publications
161
9,766
22
223
Order By: Relevance
“…An anti‐CTLA‐4 antibody named ipilimumab was approved by the FDA for treating patients with advanced melanoma in 2011 118. When ipilimumab cooperated with SRS, a median survival was increased from 4.9 to 21.3 months, along with a 2‐year survival rate from 19.7% to 47.2% 119.…”
Section: The Mechanism Of Brain Metastasismentioning
confidence: 99%
“…An anti‐CTLA‐4 antibody named ipilimumab was approved by the FDA for treating patients with advanced melanoma in 2011 118. When ipilimumab cooperated with SRS, a median survival was increased from 4.9 to 21.3 months, along with a 2‐year survival rate from 19.7% to 47.2% 119.…”
Section: The Mechanism Of Brain Metastasismentioning
confidence: 99%
“…Within the last decade, treatment of metastatic melanoma (MM) has been revolutionized by a wide array of immunotherapies including checkpoint inhibitors against CTLA-4 1 and PD-1/PD-L1 2 , 3 as well as adoptive cell therapy (ACT). 4-6 However, despite great advances, treatment responses are restricted to a fraction of patients.…”
Section: Introductionmentioning
confidence: 99%
“…Although different vaccination trials have reported a lack of a real advantage in the anti-tumor efficacy, 29 , 30 also in combination with the CTLA-4 blockade, 31 the gp100 209-217 (210M)-based vaccination, in combination with IL-2, showed clinical benefits in metastatic melanoma patients. 32 , 33 At TCR level, Schrama et al found the expansion of an oligoclonal gp100 210M-specific TCR repertoire from two patients receiving DTIC alone or in combination with low doses of IFN-α.…”
Section: Discussionmentioning
confidence: 99%